Yellow Fever: Symptoms, Vaccine, Treatment & Red Flags

Yellow fever virus is a positive-sense RNA flavivirus transmitted predominantly by day-biting Aedes or forest-associated Haemagogus mosquitoes. After replication in regional lymph nodes the virus spreads haematogenously, injures hepatocytes and renal tubular cells, disrupts endothelial integrity and triggers a cytokine storm in severe cases—producing the classic triad of jaundice, renal dysfunction and haemorrhagic diathesis when the toxic phase declares.

Transmission cycles are described as sylvatic (enzootic primate–mosquito), intermediate (peri-domestic) and urban (Aedes aegypti–driven). Urban amplification carries outbreak potential and IHR notification obligations; sylvatic exposure explains infection in ecotourism or forestry workers even without dense human caseloads.

For nurses the actionable frame is: confirm epidemiological risk, stage the patient on the illness timeline, trend objective markers of liver injury and coagulation, screen vaccination eligibility before discharge advice, and escalate early when shock or bleeding appears—management remains supportive with high-intensity monitoring rather than a targeted antiviral cure.

Aligning assessment to phase clarifies expected labs, isolation intensity and family communication.

↔On a small screen, swipe or scroll sideways to see the full table.

Mild / abortive infection: 24–72 hours of low-grade fever or feverish feeling, headache, myalgia, conjunctival injection—often without jaundice.

Toxic phase: recurrent high fever, progressive jaundice, renal failure pattern (oliguria, rising creatinine), coagulopathy (gum bleeding, epistaxis, haematemesis, melaena), shock and encephalopathy in advanced cases.

Atypical: partially vaccinated or older adults may show muted jaundice yet still develop shock—trust lactate, perfusion and platelet trends, not colour alone.

Infection follows the bite of a competent mosquito that previously fed on a viraemic host; humans amplify urban transmission when Aedes aegypti densities are high. Occupational exposure (laboratory, field ecology) is rare but documented—maintain specimen collection safety when sending blood for viral culture or molecular panels.

Non-modifiable risk includes travel to WHO-listed endemic zones; modifiable risk centres on unvaccinated status, daytime outdoor exposure without repellent, and delayed presentation after symptom onset.

Clinical assessment

Document exact travel dates, vaccination and vaccine timing, mosquito bites, occupation and similar illnesses in companions. Examine for jaundice, bleeding, encephalopathy and volume status; compare with fever with rash patterns that suggest alternate arboviruses.

Laboratory investigations

• Blood RT-PCR during the first ~7 days of illness when viraemia is expected—coordinate with microbiology for safe packaging.
• IgM serology and neutralisation assays later; interpret cautiously after vaccination or with Zika PCR–positive regions because of flavivirus cross-reactivity.
• Liver function tests, INR/PT, platelet count, haematocrit concentration, renal panel, CRP and peripheral blood smear for haemolysis or thrombocytopenia clues.
• Blood culture collection if bacterial sepsis cannot be separated on clinical grounds.

Imaging

Use chest X-ray selectively for respiratory failure, aspiration risk or alternate diagnoses—not first-line for uncomplicated viral illness.

1. Suspect compatible febrile illness in a host with endemic exposure within the incubation window.
2. Isolate using blood and body-fluid precautions when bleeding; add contact precautions for heavily soiled linen.
3. Sample early blood for RT-PCR and baseline electrolyte panel, LFTs, coagulation screen and lactate.
4. Stage severity—toxic-phase markers trigger ICU referral, invasive monitoring discussion and haematology input for product support.
5. Report confirmed cases to public health for vector control and vaccination surge planning.

• Hepatitis A—fecal–oral risk, ALT predominance, serology rather than arboviral exposure pattern.
• Q fever—occupational animal contact, often pneumonia or hepatitis without haemorrhagic shock.
• Sepsis from bacterial pathogens—positive cultures, focal source, rapid response to antibiotics.
• Severe dengue or other arboviral syndromes—compare white-cell count, haematocrit rise pattern and regional epidemiology.
• Leptospirosis or malaria in overlapping geographies—thick/thin films and targeted serology where indicated.

First-line management is aggressive supportive care: intravenous crystalloids guided by dynamic assessments, vasopressor escalation for distributive shock, correction of hypoglycaemia, renal replacement for oliguric renal failure, and blood component therapy for clinically significant bleeding. WHO’s 2025 arboviral clinical management guidance emphasises protocolised stepwise support—mirror your institution’s ICU bundles.

Antivirals and biologics listed in WHO research pathways (for example sofosbuvir or investigational monoclonal products) are not standard-of-care outside trial frameworks—defer to infectious diseases and ethics review.

Special populations: pregnancy carries high maternal–fetal mortality in wild-type infection—early critical-care consultation is essential. Older adults may exhibit exaggerated vaccine adverse events; document shared decision-making for travel vaccines. Use acetaminophen for antipyresis when hepatic synthetic function still permits; avoid nephrotoxic NSAIDs in shock. Maintain peripheral IV care and infusion hygiene during multi-day support.

Repeat LFTs, INR and platelets every 12–24 hours during toxic phase, shortening intervals if values swing rapidly. Reassess fluid balance at least 4-hourly in ICU because both under-resuscitation and fluid overload worsen outcomes. Coordinate transfusion thresholds with haematology. Review analgesic and antiemetic choices daily for accumulating organ toxicity.

Before travel-health discharge, verify yellow fever vaccine date, discuss mosquito bite prevention, document contraindications and supply patient-facing travel advice consistent with national yellow fever centre policies.

• Acute liver failure with coagulopathy and hypoglycaemia.
• Acute kidney injury requiring renal replacement.
• Multi-organ shock, disseminated intravascular coagulation pattern bleeding, secondary bacterial infection.

Single-dose live attenuated vaccine confers durable protection for most travellers when not contraindicated; immunity develops over roughly 10–30 days—plan ahead of departure. International Health Regulations may require proof of vaccination for entry to certain countries; medical exemptions require formal documentation.

Vector control complements vaccination: environmental larviciding, personal repellents, permethrin-treated uniforms for outbreak teams, and daytime bite avoidance messaging (bed nets help less because vectors bite while people are active).

Most infections resolve without sequelae. Once toxic-phase shock develops, mortality remains high even with modern ICU support—early recognition during the remission window is the strongest modifiable prognostic lever. Survivors may require prolonged physical rehabilitation after muscle wasting and critical illness neuropathy.

Travel histories are often buried in free-text notes—ask explicitly about layovers, jungle excursions and vaccination stamps. Use interpreter services when discussing vaccine risks so patients understand why deferral happens. Photograph jaundice progression only with consent and privacy safeguards; written trend lines are equally valuable for consultants.

• Hourly neurovascular perfusion and capillary refill when shock is threatened.
• Strict bleeding precautions: soft toothbrush, avoid IM injections unless essential, pad sharp corners.
• Glucose checks at least 6-hourly when hepatic synthetic failure is evolving.
• Accurate fluid balance with urine output thresholds triggering senior review per ICU protocol.

Falling platelet count, INR >1.5 without anticoagulant, rising bilirubin with deepening encephalopathy, or lactate >4 mmol/L despite fluid boluses should trigger rapid response activation and ICU co-management. Escalate antibiotics only when cultures or imaging justify bacterial superinfection—avoid blanket broad-spectrum therapy that obscures diagnosis.

Pre-treatment

Establish monitoring lines, baseline labs and strict isolation precautions; educate visitors about blood and body-fluid risks.

Post-treatment / ongoing support

Continue high-frequency vitals during toxic phase; coordinate component therapy with blood bank; protect skin integrity in oedematous patients.

Education & evaluation

Teach returning travellers red-flag symptoms for 14 days post-exposure, validate understanding of vaccine timing for future trips, and document notifications sent to public health.

These NCLEX-style clinical judgment practice items focus on the nursing priorities for this condition — recognise cues, escalate red flags, take safe action and evaluate outcomes (NCSBN Clinical Judgment Measurement Model) — through Priority FIRST, SATA, deterioration trends, multi-patient triage, ordered response, matrix matching and cloze completion on the topic of yellow fever phases, vaccine contraindications, RT-PCR timing, shock surveillance and outbreak precautions—mirroring Clinical Judgment Measurement Model reasoning from cue recognition through evaluation of outcomes.